{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:54:34Z","timestamp":1760266474002},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.ijrobp.2004.01.046","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T20:23:03Z","timestamp":1086812583000},"page":"844-851","source":"Crossref","is-referenced-by-count":5,"title":["Wr-1065, the active form of amifostine, protects hl-60 cells but not peripheral blood mononuclear cells from radiation and etoposide-induced apoptosis"],"prefix":"10.1016","volume":"59","author":[{"given":"Georges F","family":"Hatoum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Nevaldine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tej","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Phung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2004.01.046_BIB1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-8140(93)90167-7","article-title":"Ways of minimising hematopoietic damage induced by radiation and cytostatic drugs\u2014the possible role of inhibitors","volume":"29","author":"Tubiana","year":"1993","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB2","first-page":"9","article-title":"A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor","volume":"21","author":"Schiller","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1054\/bjoc.2001.1819","article-title":"Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer","volume":"84","author":"Leonard","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1524-4741.1999.00004.x","article-title":"High-dose chemotherapy with autologous stem cell rescue as a treatment modality for breast cancer","volume":"5","author":"Wingard","year":"1999","journal-title":"Breast J"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1200\/JCO.2001.19.3.621","article-title":"Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor","volume":"19","author":"Kornek","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1023\/A:1006421901192","article-title":"Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin\/cyclophosphamide plus human granulocyte colony-stimulating factor","volume":"63","author":"Kwasny","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/stem.5530160723","article-title":"Recombinant human thrombopoietin clinical development","volume":"16","author":"Jones","year":"1998","journal-title":"Stem Cells"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB8","first-page":"1519","article-title":"Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide","volume":"3","author":"Bernstein","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB9","first-page":"24","article-title":"A phase II study of doxorubicin\/paclitaxel plus G-CSF for metastatic breast cancer","volume":"11","author":"Schwartsmann","year":"1997","journal-title":"Oncology (Huntington)"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB10","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/bjc.1996.607","article-title":"Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor","volume":"74","author":"Kornek","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB11","first-page":"1363","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide","volume":"24","author":"Bernstein","year":"1996","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB12","first-page":"16","article-title":"High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy","volume":"22","author":"Vermorken","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB13","first-page":"38","article-title":"A phase I\/phase II trial of granulocyte colony-stimulating factor as bone marrow support in patients treated with vinorelbine (Navelbine)","volume":"22","author":"Havlin","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB14","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4","article-title":"Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma","volume":"91","author":"Mayers","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/10430340252769761","article-title":"Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice","volume":"13","author":"Schiedlmeier","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-642-46836-0_12","article-title":"Protection of hematopoietic stem cells from chemotherapy-induced toxicity by multidrug-resistance 1 gene transfer","volume":"144","author":"Fruehauf","year":"1998","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB17","first-page":"11","article-title":"Transfer of the MDR1 (multidrug resistance) gene","volume":"1","author":"Licht","year":"1995","journal-title":"Cytokines Mol Ther"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB18","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1038\/sj.bmt.1702368","article-title":"Clinical scale production of an improved retroviral vector expressing the human multidrug resistance 1 gene (MDR1)","volume":"25","author":"Eckert","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB19","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood.V88.9.3407.bloodjournal8893407","article-title":"High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors","volume":"88","author":"Eckert","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.iy.13.040195.002501","article-title":"Regulation of lymphocyte survival by the bcl-2 gene family","volume":"13","author":"Cory","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB21","doi-asserted-by":"crossref","first-page":"10685","DOI":"10.1073\/pnas.91.22.10685","article-title":"Bcl-2 expression during T-cell development","volume":"91","author":"Gratiot-Deans","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0014-5793(00)02324-3","article-title":"Molecular control of neutrophil apoptosis","volume":"487","author":"Akgul","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB23","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1128\/MCB.18.8.4883","article-title":"mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response","volume":"18","author":"Chao","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1006\/cyto.1999.0514","article-title":"GM-CSF rescues TF-1 cells from growth factor withdrawal-induced, but not differentiation-induced apoptosis","volume":"11","author":"Klampfer","year":"1999","journal-title":"Cytokine"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB25","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1182\/blood.V92.7.2495","article-title":"Mcl-1 expression in human neutrophils","volume":"92","author":"Moulding","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB26","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1128\/MCB.19.9.6195","article-title":"The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase\/Akt signaling pathway through a transcription factor complex containing CREB","volume":"19","author":"Wang","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4049\/jimmunol.155.1.66","article-title":"Bcl-xL rescues WEHI 231 B lymphocytes from oxidant-mediated death following diverse apoptotic stimuli","volume":"155","author":"Fang","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00282-996-0253-z","article-title":"Apoptosis in blood diseases. Review new data","volume":"38","author":"Binet","year":"1996","journal-title":"Hematol Cell Ther"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB29","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1128\/MCB.15.11.5849","article-title":"Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation","volume":"15","author":"Kan","year":"1995","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB30","first-page":"1255","article-title":"Amifostine","volume":"5","author":"Wagner","year":"1998","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s005200050150","article-title":"Radiochemotherapy with amifostine cytoprotection for head and neck cancer","volume":"6","author":"Buntzel","year":"1998","journal-title":"Supportive Care Cancer"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB32","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.10432","article-title":"Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma","volume":"94","author":"Delioukina","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB33","first-page":"95","article-title":"Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients","volume":"8","author":"Freyer","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB34","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1023\/A:1011628900089","article-title":"Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor","volume":"12","author":"Rick","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1590\/S0100-879X2000000700009","article-title":"Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas","volume":"33","author":"De Souza","year":"2000","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB36","first-page":"37","article-title":"Protection by amifostine of cyclophosphamide-induced myelosuppression","volume":"26","author":"Alberts","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00008390-199804000-00011","article-title":"Combined treatment of stage IV melanoma patients with amifostine and fotemustine\u2014a pilot study","volume":"8","author":"Mohr","year":"1998","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB38","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/(SICI)1097-0142(19970915)80:6<1134::AID-CNCR17>3.0.CO;2-9","article-title":"Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors","volume":"80","author":"Budd","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/sonc.2002.37356","article-title":"Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity","volume":"29","author":"Giatromanolaki","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB40","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1002\/1097-0142(19931201)72:11+<3495::AID-CNCR2820721617>3.0.CO;2-B","article-title":"Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy","volume":"72","author":"Capizzi","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1189\/jlb.68.1.87","article-title":"Oxidative stress as a necessary factor in room temperature-induced apoptosis of HL-60 cells","volume":"68","author":"Shimura","year":"2000","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0304-3835(98)00116-5","article-title":"Room temperature-induced apoptosis of Jurkat cells sensitive to both caspase-1 and caspase-3 inhibitors","volume":"132","author":"Shimura","year":"1998","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0014-5793(97)01327-6","article-title":"Characterization of room temperature induced apoptosis in HL-60","volume":"417","author":"Shimura","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/(SICI)1097-4652(199801)174:1<135::AID-JCP15>3.0.CO;2-E","article-title":"Potent inhibition of cell density-dependent apoptosis and enhancement of survival by dimethyl sulfoxide in human myeloblastic HL-60 cells","volume":"174","author":"Nishizawa","year":"1998","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ijrobp.2004.01.046_BIB45","doi-asserted-by":"crossref","first-page":"20003","DOI":"10.1074\/jbc.272.32.20003","article-title":"Cell density-dependent apoptosis in HL-60 cells, which is mediated by an unknown soluble factor, is inhibited by transforming growth factor beta 1 and overexpression of Bcl-2","volume":"272","author":"Saeki","year":"1997","journal-title":"J Biol Chem"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301604002184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301604002184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T20:47:32Z","timestamp":1682714852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301604002184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0360301604002184"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2004.01.046","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}